Advances in Consolidation, Stem Cell Collection, and Transplantation
Release Date: March 15, 2013
Expiration Date: March 15, 2014
Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.
With 21,700 new cases anticipated in the United States in 2012, multiple myeloma is a small population cancer that community oncology physicians may have little real practice experience in managing. This Essentials in Practice series unit has been designed to assist oncology physicians and their multidisciplinary care team members (oncology nurses and pharmacists) in navigating the management decision process for transplant-eligible patients, including tailoring treatment planning for specific patient needs, establishing treatment goals, primary therapy choices, and addressing patient concerns as to whether autologous stem cell transplant (ASCT) is a necessity while providing a rationale for which patients may benefit more from upfront ASCT and which patients might delay ASCT. Questions remain and are being investigated through clinical trials, including the impact of early versus late transplant and optimal consolidation therapies. The rationale for maintenance therapy in this population of patients is also discussed briefly as this approach has rapidly evolved into the current standard of care. Join Sergio Giralt, MD, professor of medicine at Weill Cornell College of Medicine and chief of the Adult Bone Marrow Transplant Service at the Memorial Sloan-Kettering Cancer Center in New York, as he walks you through the management planning process tailored to specific representative cases. Beth Faiman, PhDc, RN, MSN, APRN-BC, AOCN®, nurse practitioner of the multiple myeloma program at the Cleveland Clinic Foundation in Cleveland, Ohio, provides a discussion regarding the goals of therapy in newly diagnosed transplant-eligible patients, as well as anticipated side effects associated with common primary and consolidation therapies for transplant-eligible patients, including strategies to manage them and reduce their occurrence.
This activity is designed for physicians, pharmacists, physician assistants, nurses, and other health care professionals who have an interest in enhancing their clinical skills in the treatment of patients with multiple myeloma who are eligible for stem cell transplant.
Upon completion of this educational activity, participants should be able to:
- Recall clinical trial evidence for safety and efficacy, as well as trial limitations for primary as well as consolidation therapies in the context of autologous stem cell transplantation and maintenance therapy
- Recall appropriate strategies for tailoring therapy for newly diagnosed, transplant eligible patients including considerations for therapy associated side effects and strategies to reduce their occurrence
Advances in Consolidation, Stem Cell Collection, and Transplantation – Sergio Giralt, MD
Goals of Induction Therapy in Multiple Myeloma Transplant Candidates and Treatment-associated Side Effects – Beth Faiman, PhDc, RN, MSN, APRN-BC, AOCN®
Instructions for Participation and Credit
This activity is eligible for credit through March 15, 2014. After this date, this activity will expire and no further credit will be awarded.
1. Read the target audience, learning objectives, and faculty disclosures.
2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
3. Complete the educational content as designed.
4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
6. Certificates may be printed immediately after successfully completing the post-test and activity evaluation.
Sergio A. Giralt, MD
Chief, Attending Physician
Adult Bone Marrow Transplant Service
Memorial Sloan-Kettering Cancer Center
New York, New York
Dr. Sergio Giralt received his medical degree from Universidad Central de Venezuela and completed his postgraduate internship at the University Hospital of Caracas. He also completed an internal medicine residency at Good Samaritan Hospital in Cincinnati, Ohio, and a postdoctoral fellowship in hematology and oncology at The University of Texas MD Anderson Cancer Center. Dr. Giralt is currently professor of medicine at Weill Cornell College of Medicine and the chief of the Adult Bone Marrow Transplant Service in the Division of Hematologic Oncology at Memorial Sloan-Kettering Cancer Center in New York City.
Board certified in internal medicine, hematology, and medical oncology, Dr. Giralt holds memberships in several professional societies, including the American College of Physicians, American Society of Clinical Oncology, American Society of Hematology, and the North American Society of Blood and Bone Marrow Transplantation, among others. He is a highly sought speaker, lecturer, and presenter who has published hundreds of research articles and abstracts in peer-reviewed literature. Additionally, he is an editorial reviewer for several journals including Blood, Bone Marrow Transplantation, Clinical Cancer Research, Journal of Clinical Oncology, and The Oncologist.
Dr. Giralt’s research focus is on stem cell transplantation for patients with blood disorders and improving treatments for older patients who have acute and chronic leukemia. The development of these less intense and less toxic regimens has changed the standard of care for older patients throughout the world.
Beth Faiman, PhDc, RN, MSN, APRN-BC, AOCN®
Multiple Myeloma Program
Cleveland Clinic Foundation
Beth Faiman received her master of science degree in nursing and certification as an adult nurse practitioner at Kent State University, Ohio. She holds an advanced oncology nurse certification through ANCC and is a pre-doctoral research fellow at the Frances Payne Bolton School of Nursing at Case Western Reserve in Cleveland, Ohio. Ms. Faiman is currently employed as an adult nurse practitioner at the Cleveland Clinic.
A member of several professional associations including the Oncology Nursing Society, Cleveland Chapter Oncology Nursing Society, Ohio Academy of Advanced Practice Nurses, and American Association of Nurse Practitioners, Ms. Faiman is also co-chair of the Nurses Excellence Awards Committee for the Cleveland Clinic, and is current chair of the Advanced Practice Nurse Council for the Cleveland Clinic. In addition, she is an appointed delegate on the Nursing Leadership Board for the International Myeloma Foundation. Ms. Faiman is the editor-in-chief of The Oncology Nurse. She has co-authored several articles relating to the treatment of refractory and relapsing myeloma treatment and has been published in Mayo Clinic Proceedings, Clinical Journal of Oncology Nursing, and has authored several chapters related to diagnosis and management of multiple myeloma. Ms. Faiman is an active presenter and educator on the topics of multiple myeloma, general cancer diagnosis and treatment, as well as management of skeletal and other cancer complications.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-13-332-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 13-332-306
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Sergio Giralt has received consultant fees from Biokine Therapeutics Ltd., Celgene Corporation, Miltenyi Biotec, and Onyx Pharmaceuticals.
Beth Faiman has received honoraria related to speakers’ bureau activities from Celgene Corporation, Millennium Pharmaceuticals, Inc. (A wholly-owned subsidiary of Takeda Pharmaceutical Company Limited), and Onyx.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, and Eugene R. Tombler, PhD, FACME, medical director, oncology, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
Off-Label Disclosures/Investigational Disclosures
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
Dr. Giralt and Beth Faiman have indicated that they do intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.
Dr. Giralt and Beth Faiman have indicated that they do intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.
MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Millennium: The Takeda Oncology Company and Celgene Corporation.
©2013 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.